News Sentiment

BSX sentiment intelligence

Boston Scientific Corp news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 50 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 44.77 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

76/100 classification confidence.

Company focus 39

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend inactive

-0.8% over one week, -4.6% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Goldman Sachs Keeps Their Buy Rating on Boston Scientific (BSX)

Market Reaction

Balanced read

48/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 76/100 classification
One-week reaction -0.8% Price digesting
Trend fit Trend inactive -4.6% over four weeks
Fair value -43.3% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 27
Negative 10

Relevance

Why the article matched

Direct first
Direct company coverage 39
Industry context 11
Sector context 0

Sources

Coverage mix

Publishers
Market source 19
Investing.com 4
MT Newswires 3
simplywall.st 3
StockStory 3
Ad Hoc News 3
Seeking Alpha 3
The Globe and Mail 2

Event Lens

What the news is about

Classified themes
Market update 20
Earnings 18
Analyst action 6
Regulatory and legal 2
Guidance 2
Macro sensitivity 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 50
Assembly Magazine Direct company coverage

Boston Scientific Expands Medical Device R&D in Ireland With €75 Million Investment

Boston Scientific is investing €75 million to expand its research and development capabilities at its Galway facility in Ireland. This investment will enhance the site's role in developing next-generation cardiovascular and medical technologies, including new laboratories. The ex

Tone
Positive 75/100
Event
Market update
Published
16 Jul 2026 11:00
Source
Assembly Magazine
Investing.com South Africa Direct company coverage

Boston Scientific stock hits 52-week low at 42.24 USD By Investing.com

Boston Scientific's stock has plunged to a 52-week low of $42.24, marking a greater than 60% decline from its peak, despite the company's "GREAT" financial health and 17% revenue growth. This downturn, influenced by anticipated flat sales for its WATCHMAN device, has led several

Tone
Negative 36/100
Event
Earnings
Published
15 Jul 2026 14:37
Source
Investing.com South Africa
Investing.com Direct company coverage

Boston Scientific stock hits 52-week low at 42.24 USD

Boston Scientific's stock has fallen to a 52-week low of $42.24, significantly below its high of $109.50. Despite analysts maintaining "Buy" ratings, several firms have lowered price targets due to anticipated slowdowns in WATCHMAN device sales. The company currently has a "GREAT

Tone
Negative 38/100
Event
Market update
Published
15 Jul 2026 14:07
Source
Investing.com
The Globe and Mail Direct company coverage

Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM) and Boston Scientific (BSX)

RBC Capital maintained a Buy rating on Tandem Diabetes Care (TNDM) with a price target of $30.00. TD Cowen maintained a Buy rating on Boston Scientific (BSX) with a price target of $61.00, while the general analyst consensus for Boston Scientific is a Strong Buy with a $71.20 ave

Tone
Positive 73/100
Event
Analyst action
Published
15 Jul 2026 06:13
Source
The Globe and Mail
MarketWatch Direct company coverage

Boston Scientific Corp. stock underperforms Tuesday when compared to competitors

Boston Scientific Corp. (BSX) stock fell 4.52% to $42.63 on Tuesday, underperforming the broader market. This marked the third consecutive day of losses for the company's shares. The S&P 500 Index and the Dow Jones Industrial Average both saw gains on the same trading day.

Tone
Negative 29/100
Event
Market update
Published
14 Jul 2026 16:45
Source
MarketWatch
Ad Hoc News Direct company coverage

Boston Scientific stock reflects steady medtech demand

Boston Scientific's stock mirrors the long-term growth in minimally invasive medical devices, driven by its diversified portfolio across various interventional therapies. The company benefits from structural demand factors like aging populations and technological advancements lea

Tone
Positive 75/100
Event
Macro sensitivity
Published
14 Jul 2026 00:41
Source
Ad Hoc News
Ad Hoc News Direct company coverage

Boston Scientific stock reflects steady growth outlook as medical device demand expands

Boston Scientific (BSX) is positioned as a leading S&P 500 medical device company, specializing in minimally invasive therapies across cardiology, endoscopy, and neuromodulation. The company's investment appeal stems from its diversified product portfolio, global scale, and focus

Tone
Neutral 50/100
Event
Guidance
Published
13 Jul 2026 10:37
Source
Ad Hoc News
Ad Hoc News Direct company coverage

BN stock holds steady as Boston Scientific grows its medtech base

Boston Scientific Corp. (BN) is a large-cap medical device company listed on the NYSE, known for its diversified portfolio in cardiovascular, rhythm management, and interventional technologies. The company's revenue is driven by procedure volumes, product adoption, and innovation

Tone
Positive 64/100
Event
Earnings
Published
10 Jul 2026 17:21
Source
Ad Hoc News